Drugs / Longkoma Quadrivalent Recombinant Norovirus Vaccine (Pichia Pastoris)
Longkoma Quadrivalent Recombinant Norovirus Vaccine (Pichia Pastoris)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04563533 | Aug 2020 → Sep 2024 | gastroenteritis | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Longkoma Quadrivalent Recombinant Norovirus Vaccine (Pichia Pastoris) | “Phase I/IIa Clinical Trial to Evaluate the Safety, Tolerability and Immunogenicity of Longkoma Quadrivalent Recombinant Norovirus Vaccine (Pichia Pastoris) Implanted in...” NCT04563533 ↗ |
| Modality | Vaccine | “Quadrivalent Recombinant Norovirus Vaccine” NCT04563533 ↗ |